Tech Times on MSN
Oral anti-inflammatory clears phase 2 without liver risk; Rezera sets $200M IPO for NLRP3 inhibitor
Rezera's oral NLRP3 inhibitor cleared Phase 2 without the liver toxicity that halted MCC950, clearing the path for a $200M IPO and Phase 3 PAD trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results